1. Home
  2. MDWD vs CRVS Comparison

MDWD vs CRVS Comparison

Compare MDWD & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • CRVS
  • Stock Information
  • Founded
  • MDWD 2000
  • CRVS 2014
  • Country
  • MDWD Israel
  • CRVS United States
  • Employees
  • MDWD N/A
  • CRVS N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • CRVS Biotechnology: Pharmaceutical Preparations
  • Sector
  • MDWD Health Care
  • CRVS Health Care
  • Exchange
  • MDWD Nasdaq
  • CRVS Nasdaq
  • Market Cap
  • MDWD 230.6M
  • CRVS 305.4M
  • IPO Year
  • MDWD 2014
  • CRVS 2016
  • Fundamental
  • Price
  • MDWD $19.51
  • CRVS $3.91
  • Analyst Decision
  • MDWD Strong Buy
  • CRVS Strong Buy
  • Analyst Count
  • MDWD 2
  • CRVS 4
  • Target Price
  • MDWD $35.00
  • CRVS $15.00
  • AVG Volume (30 Days)
  • MDWD 55.3K
  • CRVS 1.2M
  • Earning Date
  • MDWD 08-13-2025
  • CRVS 08-05-2025
  • Dividend Yield
  • MDWD N/A
  • CRVS N/A
  • EPS Growth
  • MDWD N/A
  • CRVS N/A
  • EPS
  • MDWD N/A
  • CRVS N/A
  • Revenue
  • MDWD $19,213,000.00
  • CRVS N/A
  • Revenue This Year
  • MDWD $20.80
  • CRVS N/A
  • Revenue Next Year
  • MDWD $26.92
  • CRVS N/A
  • P/E Ratio
  • MDWD N/A
  • CRVS N/A
  • Revenue Growth
  • MDWD N/A
  • CRVS N/A
  • 52 Week Low
  • MDWD $14.14
  • CRVS $1.75
  • 52 Week High
  • MDWD $24.00
  • CRVS $10.00
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 42.75
  • CRVS 55.29
  • Support Level
  • MDWD $19.13
  • CRVS $3.55
  • Resistance Level
  • MDWD $19.87
  • CRVS $4.38
  • Average True Range (ATR)
  • MDWD 0.61
  • CRVS 0.31
  • MACD
  • MDWD -0.27
  • CRVS -0.01
  • Stochastic Oscillator
  • MDWD 25.43
  • CRVS 61.68

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Share on Social Networks: